GlassScriptPhysician profile
Maram Khalifa
NPI 1528441169
$1,048.95
in general payments reported to CMS, 2019-2025
8 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $58.81 · 2024: $340 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $657 · Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $656.97 |
| Food and Beverage | $391.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $656.97 | 2024-2025 | Actis |
| Novo Nordisk INC | $106.47 | 2025 | |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Amgen INC. | $49.99 | 2025 | Evenity |
| Tandem Diabetes Care, INC. | $41.93 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Gilead Sciences, INC. | $34.64 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.17 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maram Khalifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.